May 28, 2021 11:16 AM EDT

FDA hands a CRL to drugmaker Eton after a delayed inspection — but are Covid-19 travel restrictions really the issue?

Josh Sullivan

For the second time in three years, Eton Pharmaceuticals has received a complete response letter from the FDA, this time for its dehydrated alcohol injection …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA hands a CRL to drugmaker Eton after a delayed inspection — but are Covid-19 travel restrictions really the issue?

Josh Sullivan

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA hands a CRL to drug­mak­er Eton af­ter a de­layed in­spec­tion — but are Covid-19 trav­el re­stric­tions re­al­ly the is­sue?

Josh Sullivan

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA hands a CRL to drugmaker Eton after a delayed inspection — but are Covid-19 travel restrictions really the issue?

Applied Therapeutics' rare disease drug gets a CRL

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Novartis to cut 139 jobs in NJ as part of commercial refocus